Clinical Trial Update: Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma [Phase 1]

View source ↗

Summary

This clinical trial update discusses MEDI-570, an anti-ICOS monoclonal antibody, in relapsed or refractory peripheral T-cell lymphoma follicular variant and ang…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Peripheral T-cell Lymphoma

Drugs mentioned

• MEDI-570 (ICOS-targeting monoclonal antibody)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Status: ACTIVE_NOT_RECRUITING